Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease.

Aged Alzheimer Disease / blood Amyloid beta-Peptides Biomarkers / blood Brain / metabolism Cerebral Amyloid Angiopathy / diagnosis Cognition / physiology Cohort Studies Female Humans Machine Learning Male Memory / physiology Peptide Fragments Positron-Emission Tomography
Alzheimer's disease Amyloid PET Classification and regression trees (CART) Machine learning Plasma amyloid β Simoa immunoassay Subjective memory complainers

Journal

Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978

Informations de publication

Date de publication:
06 2019
Historique:
received: 16 11 2018
revised: 20 03 2019
accepted: 25 03 2019
pubmed: 23 5 2019
medline: 23 6 2020
entrez: 23 5 2019
Statut: ppublish

Résumé

Blood-based biomarkers of pathophysiological brain amyloid β (Aβ) accumulation, particularly for preclinical target and large-scale interventions, are warranted to effectively enrich Alzheimer's disease clinical trials and management. We investigated whether plasma concentrations of the Aβ The receiver operating characteristic curve and machine learning showed a balanced accuracy of 76.5% and 81%, respectively, for the plasma Aβ Our results encourage an independent validation cohort study to confirm the indication that the plasma Aβ

Identifiants

DOI: 10.1016/j.jalz.2019.03.009 PMID: 31113759
pubmed: 31113759
pii: S1552-5260(19)30082-2
doi: 10.1016/j.jalz.2019.03.009
pii:
doi:

Substances chimiques

Amyloid beta-Peptides 0
Biomarkers 0
Peptide Fragments 0
amyloid beta-protein (1-40) 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

764-775

Subventions

Organisme : Medical Research Council
ID : MR/L023784/2
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/P005748/1
Pays : United Kingdom

Investigateurs

H Bakardjian (H)
H Benali (H)
H Bertin (H)
J Bonheur (J)
L Boukadida (L)
N Boukerrou (N)
E Cavedo (E)
P Chiesa (P)
O Colliot (O)
B Dubois (B)
M Dubois (M)
S Epelbaum (S)
G Gagliardi (G)
R Genthon (R)
M O Habert (MO)
H Hampel (H)
M Houot (M)
A Kas (A)
F Lamari (F)
M Levy (M)
S Lista (S)
C Metzinger (C)
F Mochel (F)
F Nyasse (F)
C Poisson (C)
M C Potier (MC)
M Revillon (M)
A Santos (A)
K S Andrade (KS)
M Sole (M)
M Surtee (M)
Thiebaud de Schotten M (T)
A Vergallo (A)
N Younsi (N)
Lisi Flores Aguilar (LF)
Claudio Babiloni (C)
Filippo Baldacci (F)
Norbert Benda (N)
Keith L Black (KL)
Arun L W Bokde (ALW)
Ubaldo Bonuccelli (U)
Karl Broich (K)
Francesco Cacciola (F)
Juan Castrillo (J)
Enrica Cavedo (E)
Roberto Ceravolo (R)
Patrizia A Chiesa (PA)
Jean-Christophe Corvol (JC)
Augusto Claudio Cuello (AC)
Jeffrey L Cummings (JL)
Herman Depypere (H)
Bruno Dubois (B)
Andrea Duggento (A)
Valentina Escott-Price (V)
Howard Federoff (H)
Maria Teresa Ferretti (MT)
Massimo Fiandaca (M)
Richard A Frank (RA)
Francesco Garaci (F)
Hugo Geerts (H)
Filippo S Giorgi (FS)
Manuela Graziani (M)
Marion Haberkamp (M)
Marie-Odile Habert (MO)
Harald Hampel (H)
Karl Herholz (K)
Eric Karran (E)
Seung H Kim (SH)
Yosef Koronyo (Y)
Maya Koronyo-Hamaoui (M)
Foudil Lamari (F)
Todd Langevin (T)
Stéphane Lehéricy (S)
Simone Lista (S)
Jean Lorenceau (J)
Dalila Mango (D)
Mark Mapstone (M)
Christian Neri (C)
Robert Nisticò (R)
Sid E O'Bryant (SE)
George Perry (G)
Craig Ritchie (C)
Simone Rossi (S)
Amira Saidi (A)
Emiliano Santarnecchi (E)
Lon S Schneider (LS)
Olaf Sporns (O)
Nicola Toschi (N)
Steven R Verdooner (SR)
Andrea Vergallo (A)
Nicolas Villain (N)
Lindsay A Welikovitch (LA)
Janet Woodcock (J)
Erfan Younesi (E)

Informations de copyright

Copyright © 2019 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Auteurs

Andrea Vergallo (A)

Sorbonne University, GRC no 21, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière Hospital, Boulevard de l'hôpital, Paris, France; Brain & Spine Institute (ICM), INSERM U 1127, CNRS UMR 7225, Boulevard de l'hôpital, Paris, France; Institute of Memory and Alzheimer's Disease (IM2A), Department of Neurology, Pitié-Salpêtrière Hospital, AP-HP, Boulevard de l'hôpital, Paris, France. Electronic address: andrea.vergallo@icm-institute.org.

Lucile Mégret (L)

Sorbonnes Université, CNRS UMR 8256, INSERM ERL U1164, Team Compensation in Neurodegenerative diseases and Aging (Brain-C), Paris, France.

Simone Lista (S)

Sorbonne University, GRC no 21, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière Hospital, Boulevard de l'hôpital, Paris, France; Brain & Spine Institute (ICM), INSERM U 1127, CNRS UMR 7225, Boulevard de l'hôpital, Paris, France; Institute of Memory and Alzheimer's Disease (IM2A), Department of Neurology, Pitié-Salpêtrière Hospital, AP-HP, Boulevard de l'hôpital, Paris, France.

Enrica Cavedo (E)

Sorbonne University, GRC no 21, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière Hospital, Boulevard de l'hôpital, Paris, France; Brain & Spine Institute (ICM), INSERM U 1127, CNRS UMR 7225, Boulevard de l'hôpital, Paris, France; Institute of Memory and Alzheimer's Disease (IM2A), Department of Neurology, Pitié-Salpêtrière Hospital, AP-HP, Boulevard de l'hôpital, Paris, France.

Henrik Zetterberg (H)

Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK; UK Dementia Research Institute, London, UK.

Kaj Blennow (K)

Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.

Eugeen Vanmechelen (E)

ADx NeuroSciences NV, Ghent, Belgium.

Ann De Vos (A)

ADx NeuroSciences NV, Ghent, Belgium.

Marie-Odile Habert (MO)

Sorbonne Université, CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, Paris, France; Centre pour l'Acquisition et le Traitement des Images, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Département de Médecine Nucléaire, Paris, France.

Marie-Claude Potier (MC)

ICM Institut du Cerveau et de la Moelle épinière, CNRS UMR7225, INSERM U1127, UPMC, Hôpital de la Pitié-Salpêtrière, Paris, France.

Bruno Dubois (B)

Sorbonne University, GRC no 21, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière Hospital, Boulevard de l'hôpital, Paris, France; Brain & Spine Institute (ICM), INSERM U 1127, CNRS UMR 7225, Boulevard de l'hôpital, Paris, France; Institute of Memory and Alzheimer's Disease (IM2A), Department of Neurology, Pitié-Salpêtrière Hospital, AP-HP, Boulevard de l'hôpital, Paris, France.

Christian Neri (C)

Sorbonnes Université, CNRS UMR 8256, INSERM ERL U1164, Team Compensation in Neurodegenerative diseases and Aging (Brain-C), Paris, France.

Harald Hampel (H)

Sorbonne University, GRC no 21, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière Hospital, Boulevard de l'hôpital, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Plasma amyloid β 40/42 ratio predicts cerebral...
questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Démence › Maladie d'Alzheimer › Plasma amyloid β 40/42 ratio predicts cerebral...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Peptides bêta-amyloïdes › Plasma amyloid β 40/42 ratio predicts cerebral...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Plasma amyloid β 40/42 ratio predicts cerebral...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Plasma amyloid β 40/42 ratio predicts cerebral...
questionsmedicales.fr › Maladies métaboliques et nutritionnelles › Maladies métaboliques › Troubles de l'homéostasie des protéines › Amyloïdose › Angiopathie amyloïde cérébrale › Plasma amyloid β 40/42 ratio predicts cerebral...
questionsmedicales.fr › Phénomènes psychologiques › Processus mentaux › Cognition › Plasma amyloid β 40/42 ratio predicts cerebral...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Plasma amyloid β 40/42 ratio predicts cerebral...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Plasma amyloid β 40/42 ratio predicts cerebral...
questionsmedicales.fr › Sciences de l'information › Méthodologies informatiques › Algorithmes › Intelligence artificielle › Apprentissage machine › Plasma amyloid β 40/42 ratio predicts cerebral...
questionsmedicales.fr › Phénomènes psychologiques › Processus mentaux › Mémoire › Plasma amyloid β 40/42 ratio predicts cerebral...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Fragments peptidiques › Plasma amyloid β 40/42 ratio predicts cerebral...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Tomoscintigraphie › Tomographie par émission de positons › Plasma amyloid β 40/42 ratio predicts cerebral...